Microcap Ledger AIM ImmunoTech Inc. $AIM
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Ocala, FL
- Fiscal year end
- December 31
- Shares outstanding
- 30,442,139 [10-Q 2026-08-07]
What the company doesAI summary of filing
AIM ImmunoTech Inc. is a clinical-stage immuno-pharma company developing therapeutics for cancers, viral diseases, and immune-deficiency disorders. The company's primary product, Ampligen (rintatolimod), is a double-stranded RNA molecule under investigation for pancreatic cancer, other solid tumors, and viral diseases; it is approved for commercial sale in Argentina for severe chronic fatigue syndrome but not approved by the FDA in the United States. The company also markets Alferon N Injection (natural alpha interferon), an FDA-approved product for genital warts. AIM is pre-revenue from its investigational products and generates no material revenues from approved products. [10-K 2026-03-27]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $48.0K | −$6.81M | −$7.31M | $9.90M | [10-Q 2026-08-07] |
| FY ended Dec 2025 | $88.0K | −$13.96M | −$10.96M | $2.98M | [10-K 2026-03-27] |
| FY ended Dec 2024 | $170.0K | −$17.32M | −$14.89M | $1.70M | [10-K 2026-03-27] |
- Quarterly cash burn
- −$3.65M
- Cash runway Estimate
- ~8.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 63,706,446 | [10-Q 2024-11-14] |
| 2025-03-24 | 72,290,030 | [10-K 2025-03-27] |
| 2025-05-13 | 76,423,889 | [10-Q 2025-05-15] |
| 2025-08-12 | 2,708,688 | [10-Q 2025-08-14] |
| 2025-11-14 | 2,853,114 | [10-Q 2025-11-17] |
| 2026-03-25 | 8,147,782 | [10-K 2026-03-27] |
| 2026-05-13 | 14,563,515 | [10-Q 2026-05-15] |
| 2026-08-07 | 30,442,139 | [10-Q 2026-08-07] |
- Shelf registration
- S-1 filed 2026-06-18; declared effective 2026-06-23 [S-1 2026-06-18]
Listing status
Current status: 4 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-06-20. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-06-20 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-20] |
| 2025-06-12 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-12] |
| 2025-04-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-07] |
| 2024-12-17 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-12-17] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-17 | Equels Thomas K | buy | 24,000 | $0.21 | [4 2026-09-18] |
| 2026-09-16 | Equels Thomas K | buy | 11,000 | $0.21 | [4 2026-09-17] |
| 2026-09-15 | Equels Thomas K | buy | 22,000 | $0.22 | [4 2026-09-16] |
| 2026-09-14 | Equels Thomas K | buy | 5,900 | $0.22 | [4 2026-09-15] |
| 2026-03-12 | Equels Thomas K | other | 25,000 | — | [4 2026-03-16] |
| 2026-03-12 | Chemerow David I. | other | 25,000 | — | [4 2026-03-16] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-30 | DEF 14A | Proxy statement |
| 2026-09-14 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-09-10 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-09-04 | 8-K | Material agreement entered; Material agreement terminated; Unregistered sale of equity |
| 2026-08-11 | 8-K | Regulation FD disclosure |
| 2026-08-10 | 8-K | Results of operations |
| 2026-08-07 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Material agreement entered |
| 2026-08-05 | 8-K | Material agreement terminated |
| 2026-07-16 | 8-K | Shareholder vote results |
| 2026-06-25 | DEF 14A | Proxy statement |
| 2026-06-24 | 424B3 | Prospectus or prospectus supplement |
Alerts for $AIM
Email me when AIM ImmunoTech Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.